Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nektar Therapeutics has signed a new agreement with subsidiaries of Baxter International to develop new PEGylated therapeutics for hemophilia. The program will begin preclinical development in 2008.
Subscribe to our email newsletter
Under the terms of the expanded agreement, Nektar will receive up to $44 million in upfront and milestone payments, funding of research and development, and manufacturing revenues during research, clinical development, and commercialization. Nektar will also receive royalties on end product sales.
Baxter will be responsible for the development and commercialization of the product and Nektar will be responsible for the technology development used in the product including the provision of clinical and commercial PEG reagents.
This is the second agreement between Nektar and Baxter to work together on innovative therapeutics for hemophilia patients. The two companies announced their initial agreement in September, 2005 to develop PEGylated therapeutic forms of clotting proteins to treat hemophilia A.